Gene Therapy for GD2 Expressing Solid Tumors is under clinical development by Bellicum Pharmaceuticals and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy for GD2 Expressing Solid Tumors’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy for GD2 Expressing Solid Tumors overview
Gene therapy is under development for the treatment of refractory and relapsed neuroblastoma, medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma and central nervous system tumor. It is administered through intravenous route. The therapy comprises of T cells genetically modified by gammaretroviral transduction to express a chimeric antigen receptor (CAR) targeting the cells expressing ganglioside GD2 antigen and incorporated with safety switch and is based on the caspaCIDe and CID technology. The technology enables control of caspase-9 signaling. It was also under development for the treatment of osteosarcoma, rhabdomyosarcoma and melanoma
Bellicum Pharmaceuticals overview
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical-stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Its GoCAR™ technology builts a enhance effector cell proliferation and functional persistence and is designed to enlist wider immune cell engagement to target resistant tumor cells. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T-cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products for the treatment of solid tumors, hematological cancers and others. Bellicum is headquartered in Houston, Texas, the US.
For a complete picture of Gene Therapy for GD2 Expressing Solid Tumors’s drug-specific PTSR and LoA scores, buy the report here.